HOGY MEDICAL, The Current Fiscal Year Ordinary Profit Revised Downward to an Unexpected 16% Decrease

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Mon Mar 31, 2025 6:00 pm JST Revision

3593 HOGY MEDICAL CO.,LTD. 【J-GAAP】

Guidance Update Report

HOGY MEDICAL CO.,LTD. <3593> [TSE Prime] announced a performance revision after the market closed on March 31st (18:00). The consolidated ordinary profit for the fiscal year ending March 2025 has decreased 25.6%, from the previous forecast of 4.8 billion yen to 3.57 billion yen (compared to 4.24 billion yen in the previous period). This changes the outlook from an anticipated profit increase to a projection of a 15.9% decrease in profit.

Based on the downwardly revised full-year plan announced by the company, our calculation indicates that the October to March period (2H) consolidated ordinary profit has decreased 44.5%, from the previous forecast of 2.76 billion yen to 1.53 billion yen (compared to 1.87 billion yen in the same period of the previous year). This changes the outlook from an anticipated profit increase to a projection of a 18.1% decrease in profit.

Kabutan News

Guidance Update

Second Half Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2024 Prev	21,231	2,607	2,764	1,443	66.9	40	Oct 10, 2024	J-GAAP
Oct - Mar, 2024 New	19,491	1,657	1,534	23	1.1	40	Mar 31, 2025	J-GAAP
Revision Rate	-8.2%	-36.4%	-44.5%	-98.4%	-98.4%

Full Year Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2025 Prev	40,850	4,690	4,800	3,310	153.5	80	Apr 10, 2024	J-GAAP
Mar, 2025 New	39,110	3,740	3,570	1,890	87.7	80	Mar 31, 2025	J-GAAP
Revision Rate	-4.3%	-20.3%	-25.6%	-42.9%	-42.9%

Current Period Guidance

Second Half Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2023	19,564	1,794	1,872	1,072	44.2	40	Apr 10, 2024	J-GAAP
Oct - Mar, 2024 Guidance	19,491	1,657	1,534	23	1.1	40	Mar 31, 2025	J-GAAP
YoY	-0.4%	-7.6%	-18.1%	-97.9%	-97.6%

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2023	38,981	6,634	6,653	4,316	178.0	71	Apr 12, 2023	J-GAAP
Mar, 2024	39,100	4,169	4,245	2,804	115.6	80	Apr 10, 2024	J-GAAP
Mar, 2025 Guidance	39,110	3,740	3,570	1,890	87.7	80	Mar 31, 2025	J-GAAP
YoY	+0.0%	-10.3%	-15.9%	-32.6%	-24.1%